Lose weight by eating less salt! - Go on! - Try it! - You will feel so much better!
See my website
Wilde About Steroids

Read my Mensa article on Obesity and the Salt Connection

Read my Mensa article on Cruelty, Negligence and the Abuse of Power in the NHS: Fighting the System

Read about the cruel treatment I suffered at the Sheffield Dental Hospital: Long In The Toothache

You can contact me by email from my website. The site does not sell anything and has no banners, sponsors or adverts - just helpful information about how salt can cause obesity.


This blog has been exported to a new URL so that readers can leave Comments again. If you want to leave a Comment, please visit my 'new' blog, which has Comments enabled. The 'new' blog is Wilde About Obesity.

Sunday, May 13, 2007

Pfizer, the pharmaceutical company, and the National Institute for Clinical Health and Excellence will face each other in court next month.

Have a Nice day? Pfizer in court clash with British drug authority - Independent on Sunday

Extract:

"The world's largest pharmaceutical company will next month square off with Nice, the government drug-rationing body, in an unprecedented showdown in the High Court.
The case, lodged by American drugs giant Pfizer and marketing partner Eisai of Japan, marks the first time that the Government's National Institute for Clinical Health and Excellence, the entity that recommends whether drugs should be reimbursed by the NHS, has been put in the dock.


It is the clearest sign yet of a growing clash between the pharmaceutical industry and the Government over the latter's efforts to reduce the £11bn that it spends every year on medicines.

"You could look at this as a line in the sand," said a Pfizer spokesman. "This goes beyond a purely financial or commercial objective. This is about Nice itself and how they operate."

The row stems from an initial decision by Nice in 2005 to withdraw approval for the NHS to buy a class of four drugs used to treat patients with Alzheimer's disease. One of the four was Aricept, which was developed by Eisai and is co-marketed by Pfizer. The move sparked a storm of controversy, forcing Nice to reconsider its position. Last year, it gave its final appraisal, which largely stuck to the first ruling.

However, it said in its latest ruling that those in the moderate phase of the disease, rather than in the early or very late stages, would qualify. That left most of the 700,000 dementia and Alzheimer's sufferers in the UK ineligible for NHS-funded treatment.

Nice's argument was that the drugs simply were not effective enough to give good "value for money". "

You can reduce your risk of developing Alzheimer's disease by cutting down on salt and salty food. - See http://www.wildeaboutsteroids.co.uk/socio.html